Alkermes 3Q Revenues: $135.9 million (+8%) 3Q Earnings: $16.3 million (loss of $14.8 million 3Q11) YTD Revenues: $412.1 million (+59%) YTD Earnings: $22.0 million (loss of $50.3 million YTD11) Comments: Net sales of Vivitrol were $15.9 million, up 50%. Manufacturing and royalty revenues (M&R) were $118.3 million in the quarter, up 5%, and $364 million YTD, up 67%. Risperdal Consta and Invega Sustenna/Xeplion M&R revenues were $52.5 million in the quarter, up 10%. M&R revenues fr...